Press release
Rheumatoid Arthritis Market Size of 7MM was USD 27 Billion in 2021
The Rheumatoid Arthritis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Rheumatoid Arthritis market size from 2019 to 2032. The report also covers current Rheumatoid Arthritis treatment practices/algorithms, and unmet medical needs to curate the best of the opportunities and assess the market's underlying potential.
Key takeaways from the Rheumatoid Arthritis Market Report
• As per DelveInsight analysis, the rheumatoid arthritis market size in the 7MM was approximately USD 27 billion in 2021.
• According to the assessment done by DelveInsight, the estimated total rheumatoid arthritis prevalent population in the 7MM was approximately 4.7 million in 2021.
• Leading rheumatoid arthritis companies include Taisho Pharmaceuticals, R-Pharm, GlaxoSmithKline, Aclaris Therapeutics, Pfizer, Abivax, Bristol Myers Squibb, Oscotec/Genosco, Mesoblast, Pfizer Akros Pharma/Japan Tobacco, Abbvie, Horizon Therapeutics, Eli Lilly and Company, Taiho Pharmaceutical, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, SynAct Pharma, Cyxone, and others.
• The promising rheumatoid arthritis therapies in the pipeline include Ozoralizumab (TS-152), Artlegia (Olokizumab), Otilimab (GSK3196165/MOR103), Zunsemetinib (ATI-450), Ritlecitinib (PF-06651600), ABX464, Branebrutinib, Cevidoplenib (SKI-O-703), MPC-300-IV, PF-06650833, JTE -051, ABBV-154, TAS5315, MBS2320, AMT-101, AP1189, Rabeximod (Rob 803), and others.
For more insights into the Rheumatoid Arthritis Market Landscape, visit Rheumatoid Arthritis Market Therapeutics Landscape @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Rheumatoid Arthritis Overview
Rheumatoid Arthritis is a chronic, inflammatory autoimmune disease that leads to progressive and destructive polyarthritis and is characterized by chronic pain and joint destruction that usually progress from distal to more proximal joints. Rheumatoid Arthritis is the result of an immune response in which the body's immune system attacks its own healthy cells and the specific causes of Rheumatoid Arthritis are still unknown.
Recent Developmental Activities in the Rheumatoid Arthritis Treatment Landscape
• In June 2022, Cyxone received a response from a Type B Pre-IND meeting with the US FDA. The response from the FDA facilitates Cyxone to continue planning the Phase IIb study with Rabeximod in RA.
• In December 2021, Taisho Pharmaceuticals presented the interim results from a 24-week administration in Phase II/III clinical trial (OHZORA study) of ozoralizumab in adult patients with RA at the annual meeting of the Japanese Society for Clinical Rheumatology and Related Research.
Rheumatoid Arthritis Epidemiology Segmentation in the 7MM
• Total Rheumatoid Arthritis Prevalent Cases
• Total Rheumatoid Arthritis Diagnosed Prevalent Cases
• Rheumatoid Arthritis Gender-specific Prevalent Cases
• Rheumatoid Arthritis Age-specific Prevalent Cases
• Rheumatoid Arthritis Severity-specific Prevalent Cases
• Rheumatoid Arthritis Patients on Targeted Therapies
• Rheumatoid Arthritis Line-Wise Treated Cases
To know more information of the Rheumatoid Arthritis Epidemiology Segmentation of the report, click here for Rheumatoid Arthritis Epidemiology Insights @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Rheumatoid Arthritis Treatment Market
Over the last few years, there has been a dramatic improvement in rheumatoid arthritis outcomes as a direct result of paradigm shifts in rheumatoid arthritis treatment. At the moment, the main rheumatoid arthritis treatment options are Medicine (for long-term relief of symptoms and slowing the progression of the condition), Supportive treatments (including physiotherapy and occupational therapy, to help keep the patient mobile and manage any problems related to daily activities), and Surgery (to correct any joint problems that develop over a period of time). Nonsteroidal anti-inflammatory drugs (NSAIDs) are typically used only for symptomatic treatment until a rheumatoid arthritis diagnosis is established because they reduce pain and stiffness in patients but have no effect on disease progression.
Rheumatoid Arthritis Market Dynamics
The dynamics of the rheumatoid arthritis market is anticipated to change in the future due to the increasing awareness and expected increase in investment in the R&D activities by the leading companies working in the rheumatoid arthritis market space. Moreover, current therapies, such as biological DMARDs, have shown promising results in treating rheumatoid arthritis patients, and market penetration is expected to increase in the future, driving rheumatoid arthritis market growth.
Browse More Related Reports of the Rheumatoid Arthritis Market Research Reports, click here for Rheumatoid Arthritis Market Forecast @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Rheumatoid Arthritis Market Research Report
• Coverage- 7MM
• Companies- Taisho Pharmaceuticals, R-Pharm, GlaxoSmithKline, Aclaris Therapeutics, Pfizer, Abivax, Bristol Myers Squibb, Oscotec/Genosco, Mesoblast, Pfizer Akros Pharma/Japan Tobacco, Abbvie, Horizon Therapeutics, Eli Lilly and Company, Taiho Pharmaceutical, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, SynAct Pharma, Cyxone, and others.
• Rheumatoid Arthritis Pipeline Therapies- Ozoralizumab (TS-152), Artlegia (Olokizumab), Otilimab (GSK3196165/MOR103), Zunsemetinib (ATI-450), Ritlecitinib (PF-06651600), ABX464, Branebrutinib, Cevidoplenib (SKI-O-703), MPC-300-IV, PF-06650833, JTE -051, ABBV-154, TAS5315, MBS2320, AMT-101, AP1189, Rabeximod (Rob 803), and others.
• Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis Market Drivers and Barriers
• Rheumatoid Arthritis Market Access and Reimbursement, Unmet Needs, Future Perspectives
Read the Full Research Report of the Rheumatoid Arthritis Market Forecast Report, click here for Rheumatoid Arthritis Market Drivers and Barriers @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. SWOT Analysis
6. Epidemiology and Market Forecast Flow Methodology
7. RA Market Overview at a Glance
8. Disease Background and Overview
9. Treatment and Management of RA
10. Guidelines for Management of RA with Synthetic and Biological Disease-modifying Antirheumatic Drugs (European Alliance of Associations for Rheumatology, 2019)
11. Treatment Guidelines for RA (National Institute for Health and Care Excellence, 2021)
12. Guidelines for Management of RA (American College of Rheumatology, 2021)
13. Clinical Practice Guidelines for RA (Italian Society for Rheumatology, 2019)
14. Guidelines for the use of methotrexate in patients with RA (Japan College of Rheumatology (JCR), 2016)
15. Treatment Algorithm
16. Epidemiology and Patient Population of 7MM
17. Patient Journey
18. Key Endpoints in RA Clinical Trials
19. Marketed Drugs
20. Emerging Drugs
21. Rheumatoid arthritis: 7MM Market Analysis
22. Market Drivers
23. Market Barriers
24. Unmet Needs
25. Market Access and Reimbursement of Rheumatoid Arthritis Therapies
26. KOL Views
27. Appendix
28. DelveInsight Capabilities
29. Disclaimer
30. About DelveInsight
Consult with our Business Expert regarding "Rheumatoid Arthritis Market Landscape" @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Trending Market Reports in 2023
Healthcare Partner Identification Services @ https://www.delveinsight.com/consulting/partner-identification-services
Medical Marijuana Market @ https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Oncolytic Virus Cancer Therapy Pipeline @ https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021
Overactive Bladder Syndrome Market @ https://www.delveinsight.com/report-store/overactive-bladder-market
Pediatric Growth Hormone Deficiency PGHD Market @ https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market
Percutaneous Arterial Closure Device Market @ https://www.delveinsight.com/report-store/percutaneous-arterial-closure-device-market
Ranibizumab Biosimilars Insight @ https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
Schistosomiasis Market @ https://www.delveinsight.com/report-store/schistosomiasis-market
Stem Cell Market @ https://www.delveinsight.com/report-store/stem-cell-market
Superficial Punctate Keratitis Market @ https://www.delveinsight.com/report-store/superficial-punctate-keratitis-market
Technical Due Diligence @ https://www.delveinsight.com/consulting/due-diligence-services
Transient Ischemic Attack Market @ https://www.delveinsight.com/report-store/transient-ischemic-attack-market
Wilms Tumor Market @ https://www.delveinsight.com/report-store/wilms-tumor-market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rheumatoid Arthritis Market Size of 7MM was USD 27 Billion in 2021 here
News-ID: 2984927 • Views: …
More Releases from DelveInsight Business Research
Primary Biliary Cholangitis Market Expected to Experience Major Growth by 2034, …
DelveInsight's "Primary Biliary Cholangitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Primary Biliary Cholangitis, historical and forecasted epidemiology as well as the Primary Biliary Cholangitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Primary Biliary Cholangitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Primary Biliary Cholangitis…
Advanced Renal Cell Carcinoma Pipeline 2025: Therapies, MOA Insights, and Key Cl …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Advanced Renal Cell Carcinoma pipeline constitutes 50+ key companies continuously working towards developing 60+ Advanced Renal Cell Carcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Advanced Renal Cell Carcinoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across…
Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis b …
DelveInsight's "Alport Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Alport Syndrome, historical and forecasted epidemiology as well as the Alport Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Alport Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alport Syndrome Market Forecast
https://www.delveinsight.com/sample-request/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Angioedema Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA a …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Angioedema pipeline constitutes 20+ key companies continuously working towards developing 20+ Angioedema treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Angioedema Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Rheumatoid
Rheumatoid Arthritis Pipeline Outlook Report 2024
DelveInsight's, "Rheumatoid Arthritis Pipeline Insight 2024" report provides comprehensive insights about 95+ companies and 100+ pipeline drugs in the Rheumatoid Arthritis pipeline landscape. It covers the Rheumatoid Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Rheumatoid Arthritis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the…
Rheumatoid Arthritis Therapeutics Market - Relieving Pain, Restoring Mobility: R …
Newark, New Castle, USA: The "Rheumatoid Arthritis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Rheumatoid Arthritis Therapeutics Market: https://www.growthplusreports.com/report/rheumatoid-arthritis-therapeutics-market/7891
This latest report researches the industry structure,…
How To Cure Rheumatoid Arthritis 2021 ?
Grocare® launches new kit to manage Rheumatoid Arthritis
- New findings support research-based kit for management of Rheumatoid Arthritis
Pune, May 13, 2021: Pune-based Grocare® has recently launched an advanced research-based kit that alleviates and controls Rheumatoid Arthritis, conditions. This kit contains Absogen®, GC® and Acidim® designed to correct mitochondrial imbalance, build immunity and balance PH, respectively.
Grocare® is a pharmaceutical company that has conducted extensive research on Rheumatoid Arthritis. The company’s data…
Major Advancements| Competitor Landscape: Rheumatoid Arthritis
Researchmoz added Most up-to-date research on "Competitor Landscape: Rheumatoid Arthritis" to its huge collection of research reports.
Competitor Landscape: Rheumatoid Arthritis
Summary
Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the Rheumatoid Arthritis (RA) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during…
Rheumatoid Arthritis Drug Market Rheumatoid Arthritis Clinical Pipeline Report 2 …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Antirheumatoids: Call of Rheumatoid Arthritis
1.1 Prologue towards Rheumatoid Arthritis
1.2 Obtainable Treatment for Rheumatoid Arthritis
Molecular Mechanism of Antirheumatoids
2.1 Purpose of DMARDs in Rheumatoid Arthritis
2.2 Role of Biological Agents in Rheumatoid Arthritis
2.2.1 TNF- Inhibitors
2.2.2 Interleukin -1 and IL-6 Blockers
Classification of Rheumatoid Arthritis Drugs
3.1…
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the…
